Curanex Pharmaceuticals

Curanex Pharmaceuticals is a preclinical, developmental-stage pharmaceutical company focused on pharmaceutical-grade botanical drugs for inflammatory and immune diseases. Its lead product, Phyto-N, is a botanical extract with a long safety record in China for treating inflammatory diseases and validated in animal models for six diseases, most notably moderate-to-severe ulcerative colitis. Preclinical studies in animal models have shown therapeutic activity in multiple inflammatory conditions, acting through "multiple biological pathways". Human clinical trials (Phase I) are planned but have not yet begun in the US as of the IPO in August 2025. The company went public on Nasdaq (CURX) in August 2025.